

#5

## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Toshikazu NAKAMURA et al

Appln. No.: 09/674,377

Group Art Unit: 0000

Filed: October 30, 2000

Examiner: Unknown

For: NEOVASCULARIZATION INHIBITORS

SUBMISSION OF MISSING REQUIREMENTS OF APPLICATION

ATTN: APPLICATION BRANCH

Assistant Commissioner

for Patents

Washington, D.C. 20231

Sir:

In the Communication dated May 1, 2001, it is noted that a DOS version diskette (containing the Sequence Listing) was not provided by Applicants at the time the Sequence Listing was submitted on October 30, 2000.

In light of the above, the U.S. Patent and Trademark Office has now issued a "Notice of Missing Requirements under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US)", dated May 17, 2001, and requests that the DOS version diskette be submitted on or before July 17, 2001.

Therefore, Applicants would like to note that a DOS version diskette containing the Sequence Listing was originally submitted to the U.S. Patent and Trademark Office on October 30, 2000 (as evidenced by the date-stamped mailroom receipt, a copy of which is attached hereto).

**SUBMISSION OF MISSING REQUIREMENTS  
OF APPLICATION  
U.S. Appln. No. 09/674,377**

However, for the Examiner's convenience, Applicants again file simultaneously herewith a DOS version diskette containing the Sequence Listing.

The Assistant Commissioner is hereby authorized to charge any underpayment or credit any overpayment to Deposit Account No. 19-4880. A duplicate copy of this paper is attached.

Respectfully submitted,

*Waddell A. Biggart* / *Quet*  
Waddell A. Biggart / *Martin*  
Registration No. 24,861 #46,903

**SUGHRUE, MION, ZINN,  
MACPEAK & SEAS, PLLC**  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037-3202  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

Date: June 7, 2001

97

**PCT/JP99/01834, filed April 6, 1999**  
**REQUEST OF EARLY NOTIFICATION OF SERIAL NUMBER**

Inventor(s): Toshikazu NAKAMURA

Title: NEOVASCULARIZATION INHIBITORS

Statement in Support of Submission in Accordance with 37 C.F.R. § 1.821.

Atty Doc. #: Q61434 Client: SAEGUSA INTERNATIONAL PATENT  
OFFICE

\*Sequence Listing 3.5" disk containing Sequence Listing

Filing Date: October 30, 2000 # Pgs. Spec/Abst: 54/1/8\* #Claims: 18

International Preliminary Examination Report

# Dwg. Sheets: 13 Decl YES Prelim Amdt NO


International Search Report PTO Form 1449

IDS/Prior Art: YES Pr Doc: NO Asgmt: NO Fee: \$1,798.00

Translation of PCT Article 34 Amendment

☒ Check Attached ☐ Charge to Deposit # 19-4880 Atty/Sec: WAB/amt

SERIAL NO.:



PTO/PCT Rec'd 07 JUN 2001

PATENT APPLICATION

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Toshikazu NAKAMURA et al

Appln. No.: 09/674,377

Group Art Unit: 0000

Filed: October 30, 2000

Examiner: Unknown

For: NEOVASCULARIZATION INHIBITORS

STATEMENT IN SUPPORT OF SUBMISSION  
IN ACCORDANCE WITH 37 C.F.R. § 1.821

Assistant Commissioner  
of Patents  
Washington, D.C. 20231

Sir:

The following statement is provided to meet the requirements of 37 C.F.R. § 1.821.

I hereby state that the content of the computer readable copy (PatentIn Version 2.1) of the Sequence Listing (attached hereto) submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, is the same as the Sequence Listing filed October 30, 2000.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge and that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

6/7/01  
\_\_\_\_\_  
Date

  
\_\_\_\_\_  
Janet M. Martineau